菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Company

Vision

Every biologic can be made.

Mission

Accelerate and transform the discovery, development and manufacturing of biologics to enable our global partners and benefit patients worldwide.

CRDMO+

Explore CRDMO+ and discover how we're reimagining the future of Contract Research, Development, and Manufacturing - dedicated to giving our clients an edge in a competitive world. Experience the power of partnership with CRDMO+. Because when you thrive, we thrive.

Enable Client Success

  • Enable client success from concept to commercial with CRO, CDO and CMO capabilities
  • Enable 1,000 molecules in development and 50 products to market

Elevate Global Network

  • Leading global biologics CRDMO with integrated and robust capacity & capabilities
  • 3 RDM hubs in EU/US, Singapore and China, and 40% capacity in EU/US and Singapore

Empower Innovative Growth

  • Make technology a competitive edge in driving your R&D breakthroughs and manufacturing efficiency
  • Continuously innovative business/operation model

Energize The Agility

  • Full speed for business success enabled by the agile organization
  • Exceed your expectations with a swift and attentive approach powered by agile talents
Our Company

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

As of December 31, 2024
402

projects in pre-clinical development stage

328

projects in early-phase clinical trials

66

projects in late-phase clinical trials

21

projects in commercial manufacturing

PROUD Culture

  • P: Passion

    Customer focus
    Positive attitude and energy
    Continuous learning

  • R: Reward

    Tackling tough tasks
    Embracing change
    Giving back to society

  • O: Ownership

    Accountability
    Excellence and efficiency
    Honesty and Ethics

  • U: Unity

    Diversity and inclusion
    Respect and communication
    Teamwork

  • D: Determination

    Strong execution
    GROWTH mindset
    Calculated risks

History & Awards

  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017

Business Ethics & IP Policy

As a leading global open-access biologics technology platform, WuXi Biologics is committed to the highest standards of ethics and integrity. Employees, officers and directors strive to deal honestly, ethically and fairly with our suppliers, customers, competitors, employees and the communities we serve worldwide. Statements regarding the Company’s products and services must not be false, misleading, deceptive or fraudulent. WuXi Biologics strives to conduct business with individuals and organizations who share our commitment to highest ethical standards and who operate in a socially and environmentally responsible manner.. 

In line with that commitment, the Company expects and encourages its employees, customers, suppliers and other stakeholders who have concerns about any suspected misconduct or malpractice within the Company to come forward and voice those concerns through the whistleblowing channel. Compliance Email: Speakup@wuxibiologics.com, and access the Wuxi Biologics reporting platform at wuxibiologics.ethicspoint.com.

《Anti-Corruption Policy of WuXi Biologics》 《WHISTLEBLOWING AND INVESTIGATION》 《THE CONFLICT OF INTEREST POLICY》

《CODE OF BUSINESS CONDUCT AND ETHICS》 《Code of Business Conduct & Ethics for Business Partners》

Preservation of your IP is our highest priority.
We have established stringent policies and procedures for IP protection and prosecution of IP violations to ensure your success and win your trust.

Our purpose in business is to enable innovation for our global partners, who keep us at the top of their confidence. IP is our shared lifeline. We guard it at WuXi Biologics with our founding principles of integrity, world-class security, zero tolerance policies, and relentless pursuit of justice against any criminal act. This is our highest priority, and we must hold ourselves accountable. We are determined to earn the trust of our partners by committing to success together.

Intellectual Property Protection is the foundation of trust between WuXi Biologics and our global customers. To that end, we have established the most stringent policies in China and in U.S. for the protection of intellectual property and for prosecution of IP violations. We guard IP with founding principles of integrity, world-class security, zero-tolerance policy enforcement, and relentless pursuit of justice against any criminal act.